Bolli P, Müller F B, Linder L, Raine A E, Resink T J, Erne P, Kiowski W, Ritz R, Bühler F R
Circulation. 1987 Jan;75(1):221-8. doi: 10.1161/01.cir.75.1.221.
The vasodilating potency of alpha-human atrial natriuretic peptide (alpha-hANP) was investigated in the forearms of 16 normotensive subjects, 22 to 48 (mean 28) years old, with the use of venous occlusion plethysmography. alpha-hANP, 0.005 to 1.5 micrograms/min/100 ml forearm volume (FAV), infused in nine dose steps into the brachial artery increased forearm blood flow (FAF; ml/min/100 ml FAV) from 2.8 +/- 0.4 (SEM) to a maximum of 9.6 +/- 1.1. Forearm vascular resistance (mean arterial pressure/FAF) decreased by 72%. The alpha-hANP dose that produced a 50% vasodilator response was 0.093 +/- 0.016 microgram/min/100 ml FAV (n = 11) and it resulted in a venous plasma concentration of ANP (pANP) of 115 +/- 7 pmol/liter (normal 2 to 80; radioreceptor assay). Intraindividually, the maximum dose of alpha-hANP induced an increase in FAF that was 60% of the maximum response to sodium nitroprusside (14.1 +/- 1.8). Combined infusions (n = 9) of maximum forearm vasodilator doses of alpha-hANP and nitroprusside increased FAF to 22.7 +/- 3.4; this additive vasodilator effect of alpha-hANP and nitroprusside is consistent with their different actions on the guanylate cyclase system. In man, the direct vasorelaxant effect of alpha-hANP occurs at concentrations within the upper normal range of pANP, suggesting a physiologic vasodilator role for alpha-hANP.
采用静脉阻断体积描记法，在16名22至48岁（平均28岁）的血压正常受试者的前臂中研究了α-人心房利钠肽（α-hANP）的血管舒张效力。以九个剂量梯度向肱动脉输注α-hANP，剂量为0.005至1.5微克/分钟/100毫升前臂容积（FAV），前臂血流量（FAF；毫升/分钟/100毫升FAV）从2.8±0.4（标准误）增加至最大值9.6±1.1。前臂血管阻力（平均动脉压/FAF）降低了72%。产生50%血管舒张反应的α-hANP剂量为0.093±0.016微克/分钟/100毫升FAV（n = 11），这导致静脉血浆中ANP（pANP）浓度为115±7皮摩尔/升（正常范围为2至80；放射受体测定法）。在个体内，α-hANP的最大剂量诱导的FAF增加量是对硝普钠最大反应的60%（14.1±1.8）。联合输注α-hANP和硝普钠的最大前臂血管舒张剂量（n = 9）使FAF增加至22.7±3.4；α-hANP和硝普钠的这种相加血管舒张作用与其对鸟苷酸环化酶系统的不同作用一致。在人体中，α-hANP的直接血管舒张作用发生在pANP正常范围上限的浓度时，提示α-hANP具有生理性血管舒张作用。 )
